Pierre Lovinfosse
Papers
1
Total Citations
23
H-Index
1
About
Pierre Lovinfosse is a leading clinical researcher in radiation oncology, with a focused expertise in stereotactic body radiotherapy (SBRT) for metastatic disease. His most influential work centers on the use of robotic CyberKnife technology to treat oligorecurrent pulmonary metastases, a paradigm-shifting approach that offers precise, non-invasive treatment for patients with limited cancer spread. In his landmark 2020 study, which has garnered 23 citations, Lovinfosse systematically evaluated treatment efficacy and toxicity, demonstrating that SBRT achieves excellent local control with minimal side effects. Critically, he analyzed how tumor characteristics, patient factors, and treatment parameters influence outcomes, providing a robust framework for clinical decision-making. This work has helped establish SBRT as a standard option for oligorecurrent lung disease, directly improving quality of life and survival for patients who previously faced limited alternatives. Lovinfosse’s contributions are particularly notable for bridging the gap between technological innovation and practical, patient-centered care—his research not only validates advanced radiotherapy techniques but also refines their application to maximize benefit while minimizing harm. For students and clinicians alike, his work exemplifies how rigorous clinical investigation can translate cutting-edge technology into tangible therapeutic advances.
Research Focus
Key Achievements
Top Papers
- 1